Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Single- and multidrug resistance mutations to reverse transcriptase and protease inhibitors - Human immunodeficiency virus type 1-infected patients from two geographical areas in Spain
Autore:
Perez-Alvarez, L; Villahermosa, ML; Cuevas, MT; Delgado, E; Manjon, N; de Parga, EV; Medrano, L; Contreras, G; Thomson, MM; Colomo, C; Taboada, JA; Najera, R;
Indirizzi:
Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Chief Viral PathogenesisDept, Madrid 28220, Spain Inst Salud Carlos III Madrid Spain 28220 enesisDept, Madrid 28220, Spain Programa Prevenc SIDA & ETS, Ayuntamiento De Madrid, Spain Programa Prevenc SIDA & ETS Ayuntamiento De Madrid Spain Madrid, Spain Direcc Xeral Saude Publ, Conselleria Sanidade & Servicios Sociais, Xunta De Galicia, Spain Direcc Xeral Saude Publ Xunta De Galicia Spain Xunta De Galicia, Spain
Titolo Testata:
JOURNAL OF HUMAN VIROLOGY
fascicolo: 3, volume: 3, anno: 2000,
pagine: 150 - 156
SICI:
1090-9508(200005/06)3:3<150:SAMRMT>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
MULTIPLE-DRUG RESISTANCE; DYNAMICS IN-VIVO; ANTIRETROVIRAL THERAPY; COMBINATION THERAPY; HIV-INFECTION; POL GENE; POPULATION; DIDANOSINE; ZIDOVUDINE; INSERTION;
Keywords:
HIV-1 genotypes; antiretroviral treatment; resistance mutations; Spanish patients;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
50
Recensione:
Indirizzi per estratti:
Indirizzo: Najera, R Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Chief Viral PathogenesisDept, Madrid 28220, Spain Inst Salud Carlos III Madrid Spain 28220 , Madrid 28220, Spain
Citazione:
L. Perez-Alvarez et al., "Single- and multidrug resistance mutations to reverse transcriptase and protease inhibitors - Human immunodeficiency virus type 1-infected patients from two geographical areas in Spain", J HUMAN VIR, 3(3), 2000, pp. 150-156

Abstract

Objectives: To describe the prevalence of genotypic resistance mutations, including single and multidrug resistance (MDR) to reverse transcriptase (RT) and protease (PR) inhibitors in treated and untreated patients from two geographical areas in Spain (Madrid and Galicia). Study Design/Methods: Resistance mutations to RT inhibitors were studied by line probe assay (LiPA) or by automated sequencing in 468 patients (Madrid, 268; Galicia, 200), and resistance mutations to PR inhibitors were studied by automated sequencing in 295 patients (Madrid, 85; Galicia, 210). Results: The proportion of resistance mutations in treated and untreated patients results were higher by the LiPA method than by sequencing. By sequencing, we detected resistance mutations to nucleoside analogue RT (NRT) inhibitors and NRT inhibitors plus nonnucleoside RT (NNRT) inhibitors in 35.4%and 17.2% of treated patients, respectively. We also detected MDR to zidovudine plus lamivudine in 13.9% of treated patients from Galicia, in 1.7% from Madrid (p < 0.001), and in 1.5% of untreated patients From Galicia. Also, we detected MDR to NRT inhibitors in 3.8% and to NNRT inhibitors in 9.1%. We found resistance mutations to PR inhibitors in 38.1%; of treated patients and in 0.9% of untreated patients. Conclusions: These findings reinforce the usefulness of testing for resistance mutations in some cases to evaluate their prevalence in a given population and in the follow-up of treated patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 06:38:55